NCT06176690View on ClinicalTrials.gov

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

July 1, 2028

Study Completion Date

June 1, 2043

Conditions
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-PositivePeripheral T-cell LymphomaAnaplastic Large Cell Lymphoma, ALK-negativeNon-Hodgkin LymphomaHodgkin Lymphoma
Interventions
BIOLOGICAL

C7R.CD30.CAR-EBVST cells

The dose is based on the number of CD30.CAR- expressing cells. In our previous study the highest dose was 4 × 10\^8 cells/m2 and we did not reach an MTD. On Day 0, patients will receive their planned dose of investigational T cell product by IV infusion over approximately 1 to 10 minutes in an expected volume of 1 to 50 mL.

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER